Influence of N-hydroxymethyl-p-isopropoxyphenylsuccinimide on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model

Epilepsy Research

Volumn 100, Issue 1-2, 2012, Pages 27-36

  Luszczki, Jarogniew J ^a,b   Kominek, Mateusz ^a,b   Florek Luszczki, Magdalena ^a   Tchaytchian, Dariusz A ^a,b   Kocharov, Sergey L ^c   Zolkowska, Dorota ^d  

^a INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c INSTITUTE OF ORGANIC CHEMISTRY   (Armenia)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiepileptic drugs; Maximal electroshock induced seizures; P Isopropoxyphenylsuccinimide derivative; Pharmacokinetic pharmacodynamic interaction

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; N HYDROXYMETHYL 4 ISOPROPOXYPHENYLSUCCINIMIDE; PHENOBARBITAL; PHENYTOIN; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG POTENTIATION; DRUG SAFETY; EVOKED RESPONSE; GRIP STRENGTH; IMMUNOASSAY; LONG TERM MEMORY; MALE; MENTAL TASK; MOTOR COORDINATION; MOTOR PERFORMANCE; MOUSE; MUSCLE STRENGTH; NERVE CONDUCTION; NERVE STIMULATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SEIZURE; TASK PERFORMANCE;

ANIMALS; ANTICONVULSANTS; AVOIDANCE LEARNING; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; DRUG SYNERGISM; ELECTROSHOCK; MALE; MICE; SEIZURES; SUCCINIMIDES;

EID: 84861528274     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2012.01.003     Document Type: Article

References (28)

1. Boissier J.R., Tardy J., Diverres J.C. A simple novel method to explore tranquilizer activity: the chimney test (in French). Med. Exp. (Basel) 1960, 3:81-84.
2. Brodie M.J., Dichter M.A. Established antiepileptic drugs. Seizure 1997, 6:159-174.
3. Cadart M., Marchand S., Pariat C., Bouquet S., Couet W. Ignoring pharmacokinetics may lead to isoboles misinterpretation: illustration with the norfloxacin-theophylline convulsant interaction in rats. Pharm. Res. 2002, 19:209-214.
4. Czapinski P., Blaszczyk B., Czuczwar S.J. Mechanisms of action of antiepileptic drugs. Curr. Top. Med. Chem. 2005, 5:3-14.
5. Deckers C.L., Czuczwar S.J., Hekster Y.A., Keyser A., Kubova H., Meinardi H., Patsalos P.N., Renier W.O., Van Rijn C.M. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000, 41:1364-1374.
6. Kaminski K., Obniska J. Synthesis and anticonvulsant properties of new 1-(2-pyridinyl)-3-substituted pyrrolidine-2,5-dione derivatives. Acta Pol. Pharm. 2008, 65:457-465.
7. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N. Engl. J. Med. 2000, 342:314-319.
8. Kwan P., Brodie M.J. Epilepsy after the first drug fails: substitution or add-on?. Seizure 2000, 9:464-468.
9. Kwan P., Brodie M.J. Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia 2004, 45:1141-1149.
10. Lange J., Rump S., Galecka E., Ilczuk I., Lechowska-Postek M., Rabsztyn T. Synthesis and properties of new cyclic derivatives of succinic acid with anticonvulsant activity. Pharmazie 1977, 32:82-84.
11. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 1949, 96:99-113.
12. Löscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002, 16:669-694.
13. Löscher W., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res. 1991, 8:79-94.
14. Löscher W., Fiedler M. The role of technical, biological, and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. VII. Seasonal influences on anticonvulsant drug actions in mouse models of generalized seizures. Epilepsy Res. 2000, 38:231-248.
15. Luszczki J.J., Antkiewicz-Michaluk L., Czuczwar S.J. Isobolographic analysis of interactions between 1-methyl-1,2,3,4-tetrahydroisoquinoline and four conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Eur. J. Pharmacol. 2009, 602:298-305.
16. Luszczki J.J., Cioczek J.D., Kocharov S.L., Andres-Mach M., Kominek M., Zolkowska D. Effects of three N-(carboxyanilinomethyl) derivatives of p-isopropoxyphenyl-succinimide on the anticonvulsant action of carbamazepine, phenobarbital, phenytoin and valproate in the mouse maximal electroshock-induced seizure model. Eur. J. Pharmacol. 2010, 648:74-79.
17. Luszczki J.J., Kocharov S.L., Czuczwar S.J. N-(anilinomethyl)-p-isopropoxyphenyl-succinimide potentiates the anticonvulsant action of phenobarbital and valproate in the mouse maximal electroshock-induced seizure model. Neurosci. Res. 2009, 64:267-272.
18. Luszczki J.J., Kocharov S.L., Czuczwar S.J. Effect of p-isopropoxyphenylsuccinimide monohydrate on the anticonvulsant action of carbamazepine, phenobarbital, phenytoin and valproate in the mouse maximal electroshock-induced seizure model. Pharmacol. Rep. 2010, 62:194-202.
19. Luszczki J.J., Mohamed M., Czuczwar S.J. 2-Phosphonomethyl-pentanedioic acid (glutamate carboxypeptidase II inhibitor) increases threshold for electroconvulsions and enhances the antiseizure action of valproate against maximal electroshock-induced seizures in mice. Eur. J. Pharmacol. 2006, 531:66-73.
20. Luszczki J.J., Ratnaraj N., Patsalos P.N., Czuczwar S.J. Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Naunyn. Schmiedebergs Arch. Pharmacol. 2006, 373:169-181.
21. Luszczki J.J., Swiader M., Czuczwar M., Kis J., Czuczwar S.J. Interactions of tiagabine with some antiepileptics in the maximal electroshock in mice. Pharmacol. Biochem. Behav. 2003, 75:319-327.
22. Meyer O.A., Tilson H.A., Byrd W.C., Riley M.T. A method for the routine assessment of fore- and hindlimb grip strength of rats and mice. Neurobehav. Toxicol. 1979, 1:233-236.
23. Obniska J., Byrtus H., Kaminski K., Pawlowski M., Szczesio M., Karolak-Wojciechowska J. Design, synthesis, and anticonvulsant activity of new N-Mannich bases derived from spirosuccinimides and spirohydantoins. Bioorg. Med. Chem. 2010, 18:6134-6142.
24. Rogawski M.A., Porter R.J. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol. Rev. 1990, 42:223-286.
25. Stables J.P., Kupferberg H.J. The NIH Anticonvulsant Drug Development (ADD) Program: preclinical anticonvulsant screening project. Molecular and Cellular Targets for Anti-epileptic Drugs 1997, 191-198. John Libbey, London, (Chapter 16). G. Avanzini, G. Regesta, P. Tanganelli, M. Avoli (Eds.).
26. Venault P., Chapouthier G., de Carvalho L.P., Simiand J., Morre M., Dodd R.H., Rossier J. Benzodiazepine impairs and beta-carboline enhances performance in learning and memory tasks. Nature 1986, 321:864-866.
27. White H.S., Woodhead J.H., Wilcox K.S., Stables J.P., Kupferberg H.J., Wolf H.H. Discovery and preclinical development of antiepileptic drugs. Antiepileptic Drugs 2002, 36-48. Lippincott Williams & Wilkins, Philadelphia. 5th ed. R.H. Levy, R.H. Mattson, B.S. Meldrum, E. Perucca (Eds.).
28. Zejc A., Obniska J., Wilimowski M., Rutkowska M., Witkowska M., Barczynska J., Kedzierska-Gozdzik L., Wojewodzki W., Orzechowska-Juzwenko K., Plawiak T. Synthesis and anticonvulsant properties of some arylsuccinate methylpyridylimides. Pol. J. Pharmacol. Pharm. 1990, 42:69-77.